Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-FA: DT-216P2 in Friedreich's Ataxia
NCT06874010Phase 2Recruiting
- Sponsor
- Design Therapeutics
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DT-216 in Friedreich's ataxia (FA), sponsored by Design Therapeutics. Started Jun 2025; status: recruiting.
02
Drugs
DT-216
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT06874010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06874010.